User profiles for Francois P. Duhoux
 | Francois P DuhouxCliniques universitaires Saint-Luc, Université catholique de Louvain Verified email at uclouvain.be Cited by 3454 |
[HTML][HTML] Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma
…, FP Duhoux, T Gevaert, P Simon… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor characteristics
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
in breast cancer to guide therapy. Anti-HER2 treatment has clear survival advantages …
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open …
Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …
showed robust activity in patients with HER2-positive metastatic breast cancer who were …
A standard set of value-based patient-centered outcomes for breast cancer: the International Consortium for Health Outcomes Measurement (ICHOM) initiative
A major challenge in value-based health care is the lack of standardized health outcomes
measurements, hindering optimal monitoring and comparison of the quality of health care …
measurements, hindering optimal monitoring and comparison of the quality of health care …
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
…, I Vaneycken, J Heemskerk, FP Duhoux… - Journal of Nuclear …, 2021 - Soc Nuclear Med
131 I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-…
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single-…
[HTML][HTML] Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine
Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early setting
of breast cancer, there is a clinical need for predictive markers of response in daily practice…
of breast cancer, there is a clinical need for predictive markers of response in daily practice…
A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor–positive breast cancer
Purpose: Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in
cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and …
cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and …
[PDF][PDF] Somatic uniparental isodisomy explains multifocality of glomuvenous malformations
Inherited vascular malformations are commonly autosomal dominantly inherited with high,
but incomplete, penetrance; they often present as multiple lesions. We hypothesized that …
but incomplete, penetrance; they often present as multiple lesions. We hypothesized that …
Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial
…, A Chan, I Deleu, M Borms, FP Duhoux… - JAMA …, 2022 - jamanetwork.com
Importance Patients with breast cancer and brain metastases (BM) have a poor prognosis
and high clinical need for novel treatments; however, historically, studies have often excluded …
and high clinical need for novel treatments; however, historically, studies have often excluded …
A randomized phase II study of anti-CSF1 monoclonal antibody lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple-negative …
Purpose: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine
plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC)…
plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC)…